pression Therapeutic use of filgrastim (recombinant human methionyl G-CSF) or GM-CSF enhances recovery of neutrophils, reduces antibiotic support and risk of infection consequent to cytotoxic treatment-induced myelosuppression or myeloablative conditioning for stem cell transplantation. [1] [2] [3] [4] [5] [6] [7] Although effective, the daily dosing regimens have disadvantages, such as variable patient compliance as well as fluctuations in neutrophil counts, especially with regard to multiple cycle chemotherapy regimens. Two new forms of G-CSF with sustained duration in vivo, pegfilgrastim and nartograstim (RO-258215), have shown that a single injection can sustain a dose-and time-dependent increase in neutrophil counts for as long as 7-10 days in humans. 8, 9 Furthermore, a single dose of pegfilgrastim improved neutrophil recovery in rodent models of chemotherapyinduced myelosuppression similar to that observed with daily injections of G-CSF. 8, 10 Both proteins have shown effective, dose-dependent mobilization of CD34+ cells in normal human volunteers. 8, 9 Recent clinical trial results suggest that a single injection of pegfilgrastim is sufficient to improve recovery from chemotherapy-induced neutropenia. [11] [12] [13] [14] [15] [16] Pegfilgrastim, due to its favorable pharmacokinetics and sustained stimulatory effect on neutrophil production, would improve concerns involving scheduling and compliance during multiple cycle cytotoxic therapy and/or mobilization of stem cells. 8, 10, 17 In order to further explore the treatment efficiency of pegfilgrastim relative to filgrastim, we investigated the ability of a single pegfilgrastim injection schedule, via intravenous (i.v.) or subcutaneous (s.c.) route, to improve neutrophil recovery after myeloablative conditioning and autologous bone marrow transplant (AuBMT) in rhesus macaques. We hypothesized that due to enhanced pharmacokinetics and predominant neutrophil-mediated clearance, a single dose of pegfilgrastim will be as efficient as daily filgrastim to correct neutropenia associated with myeloablative conditioning and AuBMT.
Materials and methods

Animals
Male rhesus monkeys, Macaca mulatta, mean weight 3.570.2 kg, were housed in individual stainless-steel cages in conventional holding rooms in the Veterinary Resources Department at the University of Maryland, Greenebaum Cancer Center. Pharmacokinetic studies in normal rhesus macaques (3) (4) 
Irradiation
Monkeys, after a prehabituation period, received total body irradiation (TBI) in Lucite s restraining chairs. Approximately, 3-4 h after bone marrow harvest, the animals received TBI at a midline tissue dose of 920 cGy (250 kVp x-irradiation at 7 cGy/min). Each monkey received a unilateral exposure of 460 cGy in the anteriorposterior position, and then was rotated 1801 at middose for completion of the 920 cGy exposure. Dosimetry was performed using paired 0.5 cm 3 ionization chambers, with calibration factors traceable to the National Institute of Standards and Technology.
Recombinant cytokines
Filgrastim, recombinant human methionyl G-CSF, was produced in Escherichia coli with a specific activity of 1 Â 10 8 U/mg. Pegfilgrastim has a 20-kDa polyethylene glycol (PEG) molecule covalently bound at the N-terminal residue of rHumetG-CSF (filgrastim). Both proteins were manufactured by Amgen Inc. (Thousand Oaks, CA, USA).
Pegfilgrastim administration protocols
Normal animal pharmacokinetic analysis. Normal animals were intravenously administered single injections of pegfilgrastim at 100 mg/kg. Peripheral blood samples were taken prior to and after administration of pegfilgrastim for determination of CBC and collection of plasma for cytokine measurement at 0.25, 0.5, 1, 2, 4, 6, and 8 h post dose on day 1 and at 24-h intervals from days 2-11.
Autologous bone marrow transplantation (AuBMT). On day 0, animals were myeloablated by TBI to 920 cGy. Within 2 h of TBI, animals were infused with approximately 1 Â 10 8 AuBM-MNC/kg bw. Beginning on day 1, the monkeys received either 0.1% autologous serum (AS) for 18 consecutive days (n ¼ 13), or single doses of pegfilgrastim via the s.c. (300 mg/kg, n ¼ 4 or 100 mg/kg, n ¼ 3) or i.v. route (300 mg/kg, n ¼ 4 or 100 mg/kg, n ¼ 4), or a single dose of filgrastim at 300 mg/kg (n ¼ 4) via the s.c. or i.v. route, or filgrastim at 10 mg/kg via the s.c. route (n ¼ 4) on a daily basis until ANC reached 3000/ml (range ¼ days 12-17).
Pharmacokinetic analysis. Plasma samples for cytokine measurement were collected from the i.v. cohort preirradiation and at predose, 0.25, 0.5, 1, 2, 4, 6, and 8 h post dose on day 1 and at 24-h intervals from days 2 to 11.
Clinical support
All animals received clinical support, which consisted of antibiotics and fresh irradiated whole blood and fluids, as needed. Gentamicin ((Elkin Sinn, an AH Robbins subsidiary, Cherry Hill, NJ, USA); (10 mg/day, i.m., qd)) was administered during the first 7 days of treatment and Baytril s ((Bayer Corporation, Shawnee Mission, KS, USA) (10 mg/kg i.m., qd)) was administered for the entire period of antimicrobial treatment. The administration of antibiotics continued until the animal maintained a WBC X1000/ml for three consecutive days and had attained an ANC X500/ml. Fresh, irradiated (1500 cGy 60 Co) whole blood (approximately 30 ml/transfusion) from a random donor pool (monkeys of 410 kg) was administered when the platelet count was o20 000/ml and the hematocrit was o18%.
Hematologic evaluations
CBC. Peripheral blood was obtained from the saphenous vein to assay complete blood (Sysmex K-4500, Long Grove, IL, USA) and differential counts (Wright-Giemsa Stain, Ames Automated Slide Stainer, Elkhart, IN, USA) for 45 days after TBI. These parameters were monitored for 45 days post TBI and AuBMT. The duration of neutropenia (ANC o500/ml) and time to recovery (day ANC reached X2000/ml after TBI), ANC nadir and antimicrobial requirements were assessed. The ANC nadir was the first lowest observed or imputed ANC that occurred at least 2 days after the first dose of study drug. The duration of neutropenia was estimated as the number of days that a subject had an observed or an imputed ANC below 500/ml. Any single observed ANC that was X500/ml and was immediately preceded and followed by ANC o500/ml was counted as a day of severe neutropenia. The time to recovery was estimated as the number of days from study day 1 until the day on which the first two consecutive observed or imputed ANC after the nadir were X2000/ml.
Statistical analysis
The Normal Scores Test was used to make a pairwise comparison of the duration of neutropenia and to evaluate the statistical significance between the nadirs, time to recovery and antimicrobial requirements. The exact P-values were obtained. The test was carried out using the software package StatXact (Cytel Software Corp., Cambridge, MA, USA).
Results
Pharmacokinetic of pegfilgrastim after s.c. and i.v. administration in normal and irradiated, AuBMT animals
The concentration-time and ANC-time profiles from the AuBMT monkeys were compared with those from the normal rhesus monkeys after single i.v. administration of 100 mg/kg pegfilgrastim. (Figure 1 ). The data for the normal monkeys were from a study conducted previously by Amgen Inc. While the mean C max value was lower for the AuBMT cohort (22007310 ng/ml, n ¼ 4) than for the normal monkeys (39307380 ng/ml, n ¼ 3), the mean AUC value was higher for the AuBMT monkeys (46 30079200 ng h/ml, n ¼ 4) than for the normal monkeys (29 10073100 ng h/ml, n ¼ 3). Pegfilgrastim was cleared from the circulation in 2 days in normal monkeys and in 8 days in the AuBMT monkeys. While the reason for the difference in the C max values is not known, the lower clearance observed in the AuBMT monkeys is likely because of a decrease in the G-CSF receptor-mediated clearance secondary to the neutropenic condition. Pharmacokinetic parameters were also evaluated for i.v. administration of pegfilgrastim and filgrastim at the 300 mg/kg dose in the AuBMT cohorts. Pegfilgrastim exhibited nonlinear pk; the clearance value (CL) decreased from 2.2270.44 ml/ h/kg to 1.8070.32 ml/h/kg when the dose increased from 100 to 300 mg/kg ( Table 1) . As expected, the clearance values for pegfilgrastim were significantly lower than that for filgrastim, 47.976.56 ml/h/kg in the AuBMT animals. Therefore, systemic exposure after pegfilgrastim administration was higher than that for filgrastim administered i.v. The respective T 1/2 values for pegfilgrastim at 100 and 300 mg/kg doses were 22.274.6 and 16.274.4 h, relative to 4.772.1 h for filgrastim.
Myeloablative conditioning with AuBMT
Single administration of pegfilgrastim in the AuBMT model. Intraverous (i.v.) or s.c. administration of pegfilgrastim at 100 or 300 mg/kg on day 1 after AuBMT significantly increased ANC recovery compared with the placebo control (Po0.001). Pegfilgrastim administered via i.v. or s.c. route at 300 mg/kg significantly shortened the duration of neutropenia (2.5 and 2.3 days, respectively) vs control (11.2 days) (Po0.001), and significantly improved C max is the maximum observed serum concentration; T max is the time of C max ; T 1/2 is the terminal half-life; AUC (0-last) is the area under the concentrationstime curve from time 0 to the time of the last detectable concentration; V c is the volume of distribution at the central compartment; and CL is the serum clearance after i.v. doses.
the ANC nadir (333 and 398/ml, respectively) vs control (63/ ml) (Po0.001). Pegfilgrastim at 300 mg/kg via the s.c. route significantly shortened the time to recovery to ANC X2000/ml (10.3 days) vs control (19.8 days) (P ¼ 0.002), whereas the time to recovery via the i.v. route (19.5 days) was similar to that for the controls (Table 2) . Pegfilgrastim administered via i.v. or s.c. route at 100 mg/ kg significantly shortened the duration of neutropenia (5.3 and 4.0 days, respectively) and improved the ANC nadir (301 and 192/ml, respectively) vs control (11.2 days, 63/ml) (Pp0.005). Neither i.v. nor s.c. administration of pegfilgrastim at this dose had a significant effect on the time to recovery to ANC X2000/ml (19.5 and 19.7 days, respectively) vs control (19.8 days)(Table 2, Figure 2) . Antibiotic requirements were significantly reduced after pegfilgrastim was administered via the i.v. or s.c. route at either the 300 mg/kg dose (7.0, 5.8 days, respectively) or the 100 mg/kg dose (8.3, 10.7 days, respectively) vs the control cohort (15.3 days) (Pp0.021).
Single administration of pegfilgrastim vs single administration of filgrastim. Pegfilgrastim administered at 300 or 100 mg/kg via i.v. or s.c. route significantly decreased the duration of neutropenia and antibiotic requirements and significantly improved the ANC nadir vs a single dose of filgrastim administered via either i.v. or s.c. at 300 mg/kg on day 1. The time to recovery to ANCX2000/ml was significantly improved (Pp0.05) after s.c. administration of pegfilgrastim at 300 mg/kg vs either i.v. or s.c. administration of filgrastim at 300 mg/kg (Table 2) .
Single administration of pegfilgrastim vs daily administration of filgrastim
Pegfilgrastim administered at 100 mg/kg on day 1 via the s.c. route significantly improved the ANC nadir compared with daily administration of filgrastim at 10 mg/kg/day (301/ml vs 135/ml, P ¼ 0.029). All other neutrophil-related parameters were equivalent when comparing single administration of pegfilgrastim at 100 mg/kg on day 1 via either the i.v. or s.c. route with daily administration of filgrastim at 10 mg/kg. When administered by either route at 300 mg/kg on day 1, pegfilgrastim significantly improved the duration of neutropenia (P ¼ 0.029) and the ANC nadir (Pp0.029) as compared with daily administration of filgrastim at 10 mg/ kg/day; however, only s.c. administration of pegfilgrastim significantly improved the time to recovery to ANCX2000/ ml (P ¼ 0.029) (Table 2, Figure 2) . The daily administration of filgrastim administered at 10 mg/kg/day until the ANC X3000/ml (range 12-17 days) after AuBMT significantly improved all neutrophil-related parameters vs the control cohort (Table 2, Figure 2 ).
Filgrastim administered on day 1 at 300 mg/kg via either route vs the placebo control cohort. Neutrophil-related parameters after i.v. administration of 300 mg/kg of filgrastim on day 1 were equivalent to those after treatment with placebo, with the exception of a significantly longer duration of neutropenia (19.5 days vs 11.2 days) (P ¼ 0.012) in the filgrastim-treated group. However, when filgrastim was administered at 300 mg/kg on day 1 via the s.c. route, there was a significant improvement in the ANC nadir (125/ ml vs 63/ml, P ¼ 0.037); the duration of neutropenia and antibiotic requirements were equivalent, and there was a significant delay in time to recovery to ANC X2000/ml (24.0 vs 19.9 days) (P ¼ 0.042) as compared to placebo controls (Table 2, Figure 2) .
Discussion
Single i.v. or s.c. administration of pegfilgrastim, given within 20 h of myeloablative conditioning and AuBMT, Table 2 Neutrophil-related parameters in autologous bone marrow transplanted rhesus monkeys treated with pegfilgrastim or filgrastim Treatment n Duration of neutropenia (day) ANC nadir (cells/ml) Time to recovery (day) Antibiotic requirements (day) Monkeys were myeloablated with total body x-irradiation (TBI) to 920 cGy and within 2 h were transplanted with approximately 1 Â 10 8 AuBM MNCs per kilogram of body weight. Animals were treated, s.c., 0.1% autologous serum ( AS), filgrastim at 10 mg/kg, s.c., qd, on days 1-18 filgrastim at 300 mg/kg, s.c. or i.v. on day 1, pegfilgrastim at 100 mg/kg, s.c. or i.v. on day 1, or filgrastim at 300 mg/kg, s.c. or i.v. on day 1 post-TBI and AuBMT. The duration of neutropenia is defined as days of ANC o500/ml. Time to recovery is the number of days required for the ANC to reach X2,000/ml. 12, 19, 20 Cheung et al 19 suggested that the duration of action for pegfilgrastim during severe neutropenia would be substantially longer than predicted by normal animal models. 19 Therefore, the radiation or chemotherapy-induced neutropenic phase would represent a condition of decreased G-CSF receptor-mediated clearance and thus provide for a longer response duration. 19 The pk and pd data of pegfilgrastim in the AuBMT models presented herein support these suggestions. Significantly, higher levels of pegfilgrastim were maintained in the neutropenic animals for the predicted 6-9 days relative to the 3-4 days in nonmyelosuppressed animals. Roskos et al 20 suggested that relative to G-CSF, the clearance of pegfilgrastim is more efficiently regulated by neutrophils due to a reduction in the linear, neutrophil-independent elimination pathway. 20 Indeed, this study substantiates the significant lower values for serum clearance and consequently terminal half-life values for pegfilgrastim than filgrastim. Therefore, during periods of chemotherapyinduced neutropenia, efficacious concentrations of pegfilgrastim are maintained until onset of hematopoietic recovery. 20 Recently, several studies including early clinical trial results have suggested equivalent efficacy of pegfilgrastim and other peg-modified G-CSFs, relative to conventional, daily administration of filgrastim in enhancing recovery of neutrophils following chemotherapy or radiation-induced myelosuppression. 8 21 have shown that a single dose of peg-modified myelopoietin (leridistim), one of the dual IL-3/G-CSF receptor agonists, can improve postirradiation neutrophil recovery in nonhuman primates in a manner equivalent to conventional daily dosing of leridistim. 21 Recent clinical trials have shown that a single dose of pegfilgrastim per chemotherapy cycle can reduce the duration of chemotherapy-induced neutropenia as safely and effectively as daily administered filgrastim. 11, [13] [14] [15] [16] Further evidence of the potential utility of pegfilgrastim was shown in a recent phase III clinical trial comparing fixed-dose pegfilgrastim 6 mg/cycle with filgrastim administered at 5 mg/kg/day.
14 A 6 mg fixed dose of pegfilgrastim per chemotherapy cycle showed efficacy comparable to that of daily filgrastim administration irrespective of patient body weight.
In summary, the clearance of pegfilgrastim is selfregulated by neutrophils such that effective serum levels are maintained over the duration of severe neutropenia and decrease with the onset of granulopoiesis. Furthermore, the stimulation of granulopoiesis by pegfilgrastim after AuBMT is equivalent via the s.c. or i.v. route of administration. The highly efficient, homeostatic selfregulation of pegfilgrastim elimination may facilitate dosing once per cycle of chemotherapy, and suggests that a single injection may be sufficient to reduce neutropenia consequent to various chemotherapeutic treatments.
